Wedbush analyst Andreas Argyrides upgraded Aquestive Therapeutics to Outperform from Neutral with a $4 price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AQST:
- Aquestive Therapeutics sees FY23 revenue $37M-$41M, consensus $37.83M
- Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives
- Aquestive Therapeutics reports Q4 EPS (23c), consensus (23c)
- Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
- Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET